<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1068</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2008-4-3-53-57</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железы</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysis of the results of prostate cancer biopsies performed after a 10-year interval</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ результатов биопсий предстательной железы, выполненных с 10-летним интервалом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Romics</surname><given-names>I.</given-names></name><name xml:lang="ru"><surname>Ромич</surname><given-names>И.</given-names></name></name-alternatives><address><country country="HU">Hungary</country></address><bio xml:lang="en"><p>Department of Urology</p></bio><bio xml:lang="ru"><p>Отделение урологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Banfi</surname><given-names>G.</given-names></name><name xml:lang="ru"><surname>Банфи</surname><given-names>Г.</given-names></name></name-alternatives><address><country country="HU">Hungary</country></address><bio xml:lang="en"><p>Department of Urology</p></bio><bio xml:lang="ru"><p>Отделение урологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Glasz</surname><given-names>T.</given-names></name><name xml:lang="ru"><surname>Гласз</surname><given-names>Т.</given-names></name></name-alternatives><address><country country="HU">Hungary</country></address><bio xml:lang="en"><p>2nd Department of Pathology</p></bio><bio xml:lang="ru"><p>2-е отделение патологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Szekely</surname><given-names>E.</given-names></name><name xml:lang="ru"><surname>Жекели</surname><given-names>Э.</given-names></name></name-alternatives><address><country country="HU">Hungary</country></address><bio xml:lang="en"><p>2nd Department of Pathology</p></bio><bio xml:lang="ru"><p>2-е отделение патологии</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Semmelweis University, Budapest</institution></aff><aff><institution xml:lang="ru">Медицинский университет Семмельвейса, Будапешт</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2008-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2008</year></pub-date><volume>4</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>53</fpage><lpage>57</lpage><history><date date-type="received" iso-8601-date="2020-02-14"><day>14</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-02-14"><day>14</day><month>02</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1068">https://oncourology.abvpress.ru/oncur/article/view/1068</self-uri><abstract xml:lang="en"><p><bold>Introduction and objective:</bold> the authors compared the results of biopsies performed in 1994 and 2004, respectively.</p><p>The analysis of the results of prostate biopsy obtained in 1994 and 2004 was carried out. Prostate cancer is the most common malignant tumor in males; its diagnostic algorithm and therapy were analyzed. The aim of the study was to compare data from the prostate biopsies performed in 1994 with those of 2004. During this decade, 4.5 fold increase of the number of prostate biopsies has been observed. In 1994, 36.2%, while in 2004, 47.5% of the biopsies proved to be a cancer. The mean age of the patients undergoing biopsy decreased from 69.7 to 62.3 years; however, the mean age of patients who were suffering from prostate cancer remained constant (70.8 vs. 71.3 years).</p><p><bold>Conclusions:</bold> Whereas in 1994 only the total level of PSA was estimated, in 2004 the diagnostic algorithm included additional measurements of free-PSA and PSA-density. Prostate biopsy was performed by a trans-rectal ultrasound guided technique unlike the blind or trans-perineal methods which were only available previously. Although the effectiveness of the prostate biopsy is improved, the diagnosis and identification of prostate cancer at a younger age remains to be a challenge. The Gleason score marking the aggressiveness of the prostate cancers was lower; therefore, more patients were found suitable for curative surgery. However, the increased mean value of PSA level indicated that patients were still rather of a more advanced stage in majority, which could only be treated by palliative therapy.</p></abstract><trans-abstract xml:lang="ru"><p>.</p></trans-abstract><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>biopsy</kwd><kwd>PSA</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Romics I., Fischer G., Bе ’ ly M. et al. Experience with prostate cancer screening. Magy Urol (Hung Urol in Hungarian) 1998;10:428—32.</mixed-citation><mixed-citation xml:lang="ru">Romics I., Fischer G., Bе ’ ly M. et al. Experience with prostate cancer screening. Magy Urol (Hung Urol in Hungarian) 1998;10:428—32.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Oliver S.E., Gunnel D., Donovan J.L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000;355:1788—9.</mixed-citation><mixed-citation xml:lang="ru">Oliver S.E., Gunnel D., Donovan J.L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000;355:1788—9.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Brawer M.K., Chetner M.P., Beatle J. et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841—5.</mixed-citation><mixed-citation xml:lang="ru">Brawer M.K., Chetner M.P., Beatle J. et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841—5.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Benson M.C., Whang I.S., Olsson C.A. et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817—21.</mixed-citation><mixed-citation xml:lang="ru">Benson M.C., Whang I.S., Olsson C.A. et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817—21.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Romics I. Prognostic factors of prostate cancer. Magy Urol (Hung Urol in Hungarian) 1998;10:103—9.</mixed-citation><mixed-citation xml:lang="ru">Romics I. Prognostic factors of prostate cancer. Magy Urol (Hung Urol in Hungarian) 1998;10:103—9.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Romics I. The technique of ultrasound guided prostate biopsy. World J Urol 2004;22:353—6.</mixed-citation><mixed-citation xml:lang="ru">Romics I. The technique of ultrasound guided prostate biopsy. World J Urol 2004;22:353—6.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273—9.</mixed-citation><mixed-citation xml:lang="ru">Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273—9.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Neal D.E., Clejan S., Sarma D. et al. Prostate specific antigen and prostatitis. Prostate 1992;20:105—11.</mixed-citation><mixed-citation xml:lang="ru">Neal D.E., Clejan S., Sarma D. et al. Prostate specific antigen and prostatitis. Prostate 1992;20:105—11.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Pajor L., Kisbenedek L., Romics I. Therapy of prostate cancer. Magy Urol (Hung Urol in Hungarian) 2003;15:46—55.</mixed-citation><mixed-citation xml:lang="ru">Pajor L., Kisbenedek L., Romics I. Therapy of prostate cancer. Magy Urol (Hung Urol in Hungarian) 2003;15:46—55.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Stamey T.A., Caldwell M., McNeal J.E. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297—301.</mixed-citation><mixed-citation xml:lang="ru">Stamey T.A., Caldwell M., McNeal J.E. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297—301.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. De Koning H.J., Auvinen A., Berenguer Sanchez A. et al. Large-scale randomized prostatae cancer screening trials: program performances in the european randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237—44.</mixed-citation><mixed-citation xml:lang="ru">De Koning H.J., Auvinen A., Berenguer Sanchez A. et al. Large-scale randomized prostatae cancer screening trials: program performances in the european randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237—44.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
